Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,531 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,531 Papers indexed
1,440 Papers AI scored
39,531 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-10-23 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39531 results
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 24.1; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Machine learning-based evaluation of prognostic factors for mortality and relapse in patients with acute lymphoblastic leukemia: a comparative simulation study.
PMID 39285373 Published: 2024-09-16 Ingested: 2026-08-02 12:02 AM BMC medical informatics and decision making
AI -
Standard 72.82
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.1; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 76.5; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

B
Optimization of osteosarcoma sample processing for epigenetic analysis: A comparative evaluation of formalin-fixed, paraffin-embedded samples with and without decalcification versus fresh tissue.
PMID 42259014 Published: 2026-06-08 Ingested: 2026-08-02 12:07 AM Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Prognostic impact of tumor-associated macrophages in pediatric Ewing sarcoma, National Cancer Institute (2010-2020).
PMID 41896958 Published: 2026-03-27 Ingested: 2026-08-02 12:06 AM World journal of surgical oncology
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Established and Emerging Therapies for High-Risk Neuroblastoma.
PMID 41746475 Published: 2026-02-26 Ingested: 2026-08-02 12:06 AM Paediatric drugs
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 94.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 60.0; human relevance: 85.0; therapeutic relevance: 59.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Current Epidemiology and Infection Characteristics of Non-Aspergillus Mold Infections: A Multicenter Study in Australia and New Zealand.
PMID 41562321 Published: 2026-07-23 Ingested: 2026-08-02 12:07 AM Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Sexual function in women with Polycystic Ovary Syndrome: the role of psychological factors.
PMID 41353588 Published: 2026-01-05 Ingested: 2026-08-02 12:12 AM The journal of sexual medicine
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 44.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 72.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 493 of 3295
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic